MGLL and delirium: Although still lacking direct evidence connecting 1-SG with delirium, both pharmacological or genetic inactivation of MAGL, have been demonstrated to alleviate neuroinflammation and neuropathology, and enhance synaptic and cognitive functions in animal models of neurodegenerative diseases (59, 60), suggesting a potential protective role against delirium.